Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 123.61% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.10M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.10M.
Fairly Valued
The company’s latest PE is -5.47, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 17.27M shares, increasing 8.83% quarter-over-quarter.